In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 6, 2008, Pages 1326-1331

  Morinaga, Yoshitomo ^a   Yanagihara, Katsunori ^a   Nakamura, Shigeki ^a   Yamamoto, Kazuko ^a   Izumikawa, Koichi ^a   Seki, Masafumi ^a   Kakeya, Hiroshi ^a   Yamamoto, Yoshihiro ^a   Yamada, Yasuaki ^a   Kohno, Shigeru ^a   Kamihira, Shimeru ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Chronic respiratory infections; Meropenem; P. aeruginosa

Indexed keywords

CEFEPIME; CEFTAZIDIME; CILASTATIN; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; SODIUM CHLORIDE; TOMOPENEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; CHRONIC DISEASE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LUNG PARENCHYMA; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLONY COUNT, MICROBIAL; HUMANS; LUNG; MALE; MICE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SERUM; THIENAMYCINS;

EID: 56649083763     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn411     Document Type: Article

References (20)

1. Ishii Y, Iwata M, Murakami H et al. Annual change of susceptibility of Pseudomonas aeruginosa isolated from lower respiratory tract or urinary tract infections against antibacterial agents. Jpn J Chemother 2004; 52: 256-64.
2. Brown NP, Draghi DC, Jones ME et al. Baseline profile of RO4908463 (CS-023) against recent isolates of target Gram-negative pathogens exhibiting lactam-resistant phenotypes from Europe (EU), 2003-2006. In: Abstracts of the Seventeenth European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, 2007. Abstract P1663.
3. Koga T, Abe T, Inoue H et al. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob Agents Chemother 2005; 49: 3239-50.
4. Thomson KS, Moland ES. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa. J Antimicrob Chemother 2004; 54: 557-62.
5. Kawamoto I, Shimoji Y, Kanno O et al. Synthesis and structure-activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety. J Antibiot (Tokyo) 2003; 56: 565-79.
6. Shibayama T, Matsushita Y, Hirota T et al. Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers. Antimicrob Agents Chemother 2006; 50: 4186-8.
7. Yanagihara K, Tomono K, Sawai T et al. Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. J Antimicrob Chemother 2000; 46: 69-72.
8. Yanagihara K, Tomono K, Sawai T et al. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997; 155: 337-42.
9. Shibayama T, Matsushita Y, Kurihara A et al. Prediction of pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in humans using animal data. Xenobiotica 2007; 37 91-102.
10. Sumita Y, Nouda H, Tada E et al. Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administered to laboratory animals. Chemotherapy (Tokyo) 1992; 40 Suppl 1: 123-31.
11. Iaconis JP, Pitkin DH, Sheikh W et al. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials. Clin Infect Dis 1997; 24 Suppl 2: S191-6.
12. Karlowsky JA, Draghi DC, Jones ME et al. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003; 47: 1681-8.
13. Jones RN, Kirby JT, Beach ML et al. Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002; 43: 239-43.
14. Turner PJ. Meropenem activity against European isolates: Report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 2008; 60: 185-92.
15. Fukasawa M, Sumita Y, Harabe ET et al. Stability of meropenem and effect of 1β-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob Agents Chemother 1992; 36 1577-9.
16. Kropp H, Sundelof JG, Hajdu R et al. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother 1982; 22: 62-70.
17. Shibayama T, Matsushita Y, Kawai K et al. Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals. Antimicrob Agents Chemother 2007; 51: 257-63.
18. Craig WA, Ebert SC. Continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother 1992; 36: 2577-83.
19. Craig W, Ebert S, Watanabe Y. Differences in time above MIC (T.MIC) required for efficacy of β-lactams in animal infection models. In: Abstracts of the Thirty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993. Abstract 88.
20. Shibayama T, Sugiyama D, Kamiyama E et al. Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters. Drug Metab Pharmacokinet 2007; 22: 41-7.